Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.
Is Hims Legit in 2026? An Honest Trust Breakdown After the FDA Letter
Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~9 min read
Key Takeaways
- Verdict: Yes, Hims is a legitimate publicly-traded telehealth company (HIMS, NYSE) with $2.35B in FY2025 revenue, 2.5M+ subscribers, and licensure in all 50 states. But it carries real compliance friction — specifically, FDA warning letter 716567 (issued Sep 9, 2025) and the Novo Nordisk partnership termination on June 24, 2025.
- Trustpilot 3.0/5 vs BBB A+ is the central paradox: Hims holds an A+ BBB rating (accredited since 2018) but has ~3,792 lifetime BBB complaints and a Trustpilot score of 3.0/5 across ~7,794 reviews. The gap is explainable — BBB grades reflect responsiveness to complaints, not satisfaction; Trustpilot captures raw sentiment.
- The Novo Nordisk signal matters: Novo terminated Hims on June 24, 2025 over compounded semaglutide marketing, but kept its parallel partnerships with Ro and LifeMD. Same drugmaker, same compliance bar, opposite verdicts.
- FDA letter 716567 is real but not existential: FDA cited Hims’ compounded semaglutide marketing claims as false or misleading under FFDCA sections 502(a) and 502(bb). It is a standard enforcement letter, not a recall, 483, or consent decree. Hims publicly committed to compliance.
- The $149 membership trap is the #1 billing complaint: Cancelling medication does not auto-cancel the $149/mo membership on some funnels. They must be cancelled independently. This is the dominant pattern across BBB filings.
- Compounded vs FDA-approved distinction: Hims’ generic sildenafil, finasteride, and SSRI lines are FDA-approved. Hard Mints, compounded semaglutide, and topical fin+min sprays are 503A/503B compounded — legal and prescribable, but not FDA-evaluated as finished products.
Yes, Hims is a legitimate publicly-traded telehealth company (HIMS, NYSE, $2.35B FY2025 revenue with 2.5M+ subscribers across all 50 states) — but customers report cancellation friction, and the September 9, 2025 FDA warning letter 716567 raised marketing-disclosure concerns specifically tied to compounded semaglutide. The Trustpilot score of 3.0/5 across ~7,794 reviews and the 3,792 lifetime BBB complaints (despite an A+ BBB rating) reflect a real but explainable reputation paradox. The single sharpest trust signal in 2026: Novo Nordisk dropped Hims on June 24, 2025 while keeping Ro and LifeMD.
What “Legit” Means for a Telehealth Brand in 2026
Calling a telehealth company “legit” is shorthand for a stack of specific regulatory, financial, and clinical facts. Here is the Hims stack, verified May 2026:
- Corporate status: Hims & Hers Health, Inc. is a publicly-traded company listed on the NYSE under ticker HIMS. The 10-K for FY2025 was filed with the SEC on February 23, 2026. Revenue of $2.35B (up 59% YoY), net income of $128M, adjusted EBITDA of $318M, and gross margin of 74%. These are audited numbers, not marketing claims.
- State medical board licensing: Hims maintains an active 50-state plus DC licensure footprint. The prescriber who reviews your intake holds an active license in your state — that is a statutory requirement, not a marketing point.
- HIPAA compliance: Hims publishes a HIPAA-compliant Notice of Privacy Practices. Intake answers are treated as protected health information (PHI), encrypted in transit and at rest.
- Clinician network: Mix of licensed MDs and nurse practitioners across both W-2 and 1099 arrangements. The W-2 share is lower than Ro’s (which is ~70% salaried per Out-of-Pocket reporting); this is a structural detail worth knowing if you care about how prescribers are compensated.
- Pharmacy operations: Hims owns and partners with 503A and 503B compounding facilities, including a wholly-owned facility in Ohio acquired in late 2023. Compounding is fully legal under federal law when performed by licensed pharmacies for individualized patient prescriptions.
By every standard regulators actually apply, Hims is a legitimate telehealth provider. The interesting question is not whether Hims is legit — it’s whether the compliance friction surfaced in 2025 changes how a 2026 buyer should think about the brand. For the full product walkthrough, see our Hims provider review.
[provider=”hims”]
Hims Is a $2.35B Public Company — Here’s What That Means
Trust in a telehealth brand starts with whether the company can actually be held accountable. A publicly-traded entity files quarterly 10-Q’s and an annual 10-K with the Securities and Exchange Commission. Material risks, including FDA actions and partnership terminations, must be disclosed to investors under federal securities law. That is a higher disclosure standard than any private telehealth competitor faces.
The 2026 financial snapshot:
- Ticker: HIMS on the New York Stock Exchange. IPO’d via SPAC merger in January 2021.
- FY2025 revenue: $2.35B, up 59% YoY from $1.48B in 2024.
- Subscribers: 2.5M+ at fiscal year end, up 13% YoY.
- Profitability: $128M net income, $318M adjusted EBITDA, 74% gross margin.
- FY2026 guidance: $2.7B-$2.9B revenue, $300M-$375M adjusted EBITDA. The deceleration vs 2025 reflects compounded-GLP-1 volume contraction following the FDA letter.
- HQ: San Francisco, CA. Founded 2017 by Andrew Dudum (current CEO).
A $2.35B revenue company with audited financials, SEC oversight, and 2.5M+ active subscribers does not fit any reasonable definition of a “scam.” The skepticism on the open web is not about whether the company is real — it’s about whether the customer experience is friction-free. Those are two different questions.
The Trustpilot 3.0 vs BBB A+ Paradox, Explained Honestly
The single most cited “is Hims legit” data point on the open web is the gap between Hims’ Trustpilot and BBB scores. Here it is honestly, verified May 2026:
| Source | Score | Sample size | What it actually measures |
|---|---|---|---|
| Trustpilot (hims.com) | 3.0/5 | ~7,794 reviews | Open-platform sentiment; skews heavily negative on cancellation friction. |
| BBB (Hims & Hers Inc.) | A+ accredited (since Feb 22, 2018) | ~3,792 lifetime complaints | Responsiveness to complaints, not customer satisfaction. |
| Yelp (SF HQ) | Mixed | ~75 reviews | Low-volume; not representative. |
| Reddit (r/Hims, r/tressless) | Polarized | Thousands of threads | Hair-loss vertical is positive; ED vertical mixed; mental-health mixed; weight-loss negative since June 2025. |
Ratings verified May 2026. Subject to change — check provider profile pages for current data.
The paradox isn’t really a paradox once you understand what each rating measures.
A BBB A+ rating doesn’t mean “customers are happy.” The BBB grade reflects how a business responds to complaints filed through BBB mediation — whether the company acknowledges, investigates, and works toward resolution. Hims has a high complaint volume (3,792 lifetime), but each complaint is formally closed through BBB’s process, which is what keeps the A+ intact. The customer-review average inside the BBB profile is markedly lower than the accreditation grade — and that’s the data point honest buyers should look at.
Trustpilot’s 3.0/5 captures unmediated sentiment. When a customer is frustrated, Trustpilot is the easiest one-click outlet. The 7,794-review sample is large enough that the 3.0/5 score is statistically meaningful, not a vocal-minority artifact. The dominant complaint themes are consistent across Trustpilot and BBB:
- Cancellation friction: Multi-click cancellation flows, confusing dashboard labeling, customer service response delays.
- The $149/mo membership trap: Some funnels enroll customers in a $149 monthly membership that is separate from medication. Cancelling the medication does NOT auto-cancel the membership — they must be cancelled independently. This is the dominant billing-confusion pattern, structurally similar to (but worse than) Ro’s $149 Ro Body issue.
- Refund disputes: Customers who cancel within hours of a shipment trigger but get charged anyway, then face delays getting refunds processed.
- Dose escalation pricing surprises: Moving from 25 mg to 50 mg sildenafil, or from one tretinoin strength to another, can shift monthly cost without an obvious confirmation step.
What is not in the complaint corpus: counterfeit medication, fake prescribers, identity theft, or clinical harm. That distinction matters. The complaints describe a billing-UX problem, not a safety or fraud problem.
If you’re a Hims customer now, the highest-leverage piece of advice in this article is in our how to cancel Hims guide — set a calendar reminder 48 hours before each renewal date.
FDA Warning Letter 716567: What It Actually Says
On September 9, 2025, the FDA issued warning letter 716567 to Andrew Dudum, CEO of Hims & Hers Health, Inc. dba Hims. The letter is publicly posted on fda.gov. Here is the plain-English breakdown.
What FDA reviewed: The Hims website during August 2025, focused on the compounded semaglutide product pages and adjacent marketing materials.
What FDA cited: Marketing claims about compounded semaglutide that the agency determined were false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Specifically:
- Language comparing compounded semaglutide to FDA-approved Wegovy in ways that implied equivalence or superior personalization without scientific substantiation.
- Failure to clearly convey that compounded products are not evaluated by FDA for safety, efficacy, or quality the way FDA-approved finished products are.
- “Personalization” framing that, in FDA’s reading, suggested clinical tailoring beyond what the compounded preparation actually represented.
What the letter is NOT: It is not a recall. It is not a Form 483 (which is an inspection observation, separate enforcement tier). It is not a consent decree. It is not an injunction. It is a standard “respond within 15 business days with your corrective plan” enforcement letter — the same category FDA issues to dozens of companies annually across pharma, food, and devices.
What Hims did: Publicly committed to responding and complying. Behind the scenes, Hims pivoted the compounded-GLP-1 marketing from “save 85% vs Wegovy” framing to “personalized doses your provider customizes” framing during Q4 2025 and Q1 2026. Compounded-GLP-1 volume reportedly contracted by roughly 40% from peak, which is part of why FY2026 revenue guidance ($2.7B-$2.9B) signals deceleration.
Why it matters for trust: The letter validates a specific criticism — Hims’ compounded-semaglutide marketing crossed a line FDA was willing to enforce — without invalidating the broader business. For a deep walkthrough of the letter and the regulatory context, see our FDA letter 716567 explainer.
The Novo Nordisk Termination: Why Ro Kept the Deal and Hims Lost It
The single sharpest trust differentiator in 2026 is what happened with Novo Nordisk.
The timeline:
- Late April 2025: Novo Nordisk and Hims announced a partnership to distribute branded Wegovy at ~$499-599/mo through the Hims platform. The deal was struck shortly after FDA declared Wegovy was no longer in shortage, which legally narrows the window for compounded semaglutide.
- June 23-24, 2025: Novo Nordisk publicly terminated the partnership after roughly one month. Novo’s press release explicitly cited (a) Hims continuing to sell compounded “knockoff” semaglutide alongside the branded product; (b) compounded API allegedly sourced from foreign suppliers in China, not FDA-authorized; (c) deceptive “personalization” marketing.
- Same window: Novo Nordisk kept its parallel branded-Wegovy partnerships with Ro and LifeMD.
HIMS stock dropped roughly 30% intraday on the announcement. Both Reuters and the major business outlets covered the split as a major credibility event.
The contrast matters because it isolates the variable. Same drugmaker. Same regulator-facing compliance bar. Same DTC telehealth distribution model. Novo’s compliance and brand teams looked across the field and concluded that Ro and LifeMD met their standards while Hims did not. That is a third-party trust verdict from a $400B-plus market-cap pharmaceutical company with a fiduciary obligation to vet every distribution channel.
This is the cleanest single-sentence test: “Hims is the telehealth platform Novo Nordisk dropped in June 2025 over compounded-semaglutide compliance — while keeping Ro and LifeMD on the same product.” A 2026 buyer who weights pharma-grade compliance signals should know that fact before signing up.
[provider=”ro”]
Hims Clinical Model: Licensed in All 50 States
The compliance friction on the marketing side does not extend to the clinical side. Hims’ prescribing model is straightforward and entirely standard for async telehealth:
- 50-state plus DC licensure. Every prescription is written by a clinician licensed in the patient’s state.
- Provider mix: Licensed MDs and NPs. Some are W-2; some are 1099. The W-2 share is lower than Ro’s. If you weight prescriber compensation structure (W-2 salaried clinicians don’t have per-script financial incentives), Ro has a slight structural edge.
- Cash-pay only. Hims does not bill insurance for any product line. Itemized receipts are available for FSA/HSA reimbursement.
- No controlled substances. Hims does not prescribe Adderall, Xanax, Ritalin, or any DEA Schedule II-IV drugs. SSRIs (sertraline, fluoxetine, escitalopram) and finasteride and PDE5 inhibitors are not controlled. The DEA telehealth flexibilities extended through 31-Dec-2026 don’t change Hims’ current product mix because none of it requires DEA flexibilities.
- Async-first. No live video by default. Provider communication is via secure messaging through the app or web portal.
Common “Is Hims a Scam” Claims, Honestly Sorted
Open-web search surfaces a few recurring claims. Here’s the sort:
- “Hims charged me $149 and I never signed up” — has merit. The $149 monthly membership separate from medication is the dominant complaint pattern. It is disclosed in checkout fine print but routinely missed. This is a billing-UX problem, not a fraud.
- “Hims is selling fake semaglutide” — partially true, more nuanced. Hims sells compounded semaglutide, which is legal under 503A and 503B compounding pathways. The FDA letter 716567 took issue with the marketing, not the existence of the compound. “Fake” is too strong; “not FDA-evaluated as a finished product” is accurate.
- “Hims doctors aren’t real” — false. Prescribers are licensed MDs and NPs verifiable through state board lookups. The async-first model is unfamiliar but it does not mean the clinicians are fake.
- “Hims canceled my subscription but kept charging me” — has merit. The cancellation-but-still-billed pattern is real, and it’s typically caused by the medication-vs-membership distinction. Cancel both separately and document each confirmation.
- “Hims got shut down by the FDA” — false. No part of Hims has been shut down. Warning letter 716567 is a corrective-action letter, not a shutdown order.
- “Hims hair loss product doesn’t work” — disputed. Reddit’s r/tressless community is generally positive on Hims’ finasteride and minoxidil offerings. Individual results vary; the product itself is FDA-approved generic finasteride and 5% minoxidil, dispensed via standard pharmacy.
Verdict: Is Hims Legit in 2026?
Yes. Hims is a legitimate publicly-traded $2.35B-revenue telehealth company with audited financials, SEC oversight, 50-state licensure, and 2.5M+ active subscribers. The FDA warning letter 716567 and the Novo Nordisk termination are real and material — they describe a compliance-friction problem on the marketing side, particularly around compounded semaglutide. They do not describe an existential threat to the business or to your safety as a customer.
Frame Hims accurately: compliance friction, not solvency risk.
If you’re choosing between Hims and Ro on trust signals alone, the Novo Nordisk verdict — Ro kept, Hims dropped — is the cleanest tiebreaker. For everything else (price, SKU mix, vertical depth), see our Hims pricing breakdown and our Is Roman legit for ED guide for the same trust framework applied to Ro.
[provider=”hims”]
Frequently Asked Questions
Is Hims a legitimate company?
Yes. Hims & Hers Health, Inc. is a publicly-traded company on the NYSE under ticker HIMS, with $2.35B in FY2025 revenue (audited 10-K filed February 23, 2026), 2.5M+ subscribers, and licensure in all 50 states plus DC. It operates compounding pharmacies under 503A and 503B federal pathways, including a wholly-owned facility in Ohio. Verified May 2026.
Is Hims a scam?
No. Hims is not a scam. It is a $2.35B-revenue publicly-traded telehealth company with audited SEC filings, 50-state medical board licensure, HIPAA-compliant operations, and 2.5M+ active subscribers. The negative reviews on Trustpilot (3.0/5 across ~7,794 reviews) and the 3,792 lifetime BBB complaints describe billing friction — the $149/mo membership separate from medication, cancellation difficulty, refund delays — not counterfeit medication or fraud.
Is Hims FDA approved?
The Hims platform itself is not “FDA approved” because FDA does not approve platforms — it approves drugs. Hims’ generic sildenafil, generic finasteride, branded Viagra, branded Cialis, and SSRI lines (sertraline, fluoxetine, escitalopram) are all FDA-approved medications dispensed through licensed pharmacies. Hims Hard Mints, compounded semaglutide, topical finasteride+minoxidil sprays, and Rx tretinoin creams are 503A/503B compounded — legal and prescribable, but not FDA-evaluated as finished products. Always check whether your specific SKU is FDA-approved or compounded.
Is Hims publicly traded?
Yes. Hims & Hers Health, Inc. trades on the New York Stock Exchange under ticker HIMS. The company went public via SPAC merger in January 2021. The most recent annual 10-K, covering FY2025, was filed with the SEC on February 23, 2026, reporting $2.35B in revenue, $128M net income, and $318M adjusted EBITDA.
Did Hims get in trouble with the FDA?
Yes. FDA issued warning letter 716567 to Hims & Hers Health, Inc. dba Hims on September 9, 2025, citing marketing claims about compounded semaglutide that the agency determined were false or misleading under FFDCA sections 502(a) and 502(bb). The letter is not a recall, Form 483, or consent decree — it is a standard corrective-action letter. Hims publicly committed to responding and complying, and pivoted its compounded-GLP-1 marketing during Q4 2025. See our FDA letter 716567 explainer.
Why did Novo Nordisk drop Hims?
On June 24, 2025, Novo Nordisk terminated its Wegovy distribution partnership with Hims, citing Hims’ continued sale of compounded “knockoff” semaglutide alongside the branded product, compounded API allegedly sourced from foreign suppliers in China, and deceptive “personalization” marketing. Critically, Novo kept its parallel partnerships with Ro and LifeMD — same drugmaker, same compliance bar, opposite verdicts. HIMS stock dropped roughly 30% intraday on the news.
Are Hims doctors real?
Yes. Hims’ clinical network consists of licensed MDs and nurse practitioners holding active state medical board licenses in the patient’s state. The mix includes both W-2 salaried clinicians and 1099 contractors. Hims is async-first — no live video by default — but the prescriber reviewing your intake and signing your prescription is verifiably licensed and identifiable through your state’s medical board lookup.
Is Hims available in all 50 states?
Yes. Hims maintains an active 50-state plus DC licensure footprint across its product lines (ED, hair loss, mental health, skincare, and weight loss). Specific SKU availability can vary state-by-state because some compounded preparations are restricted by state pharmacy boards. The platform will tell you at intake if a specific product cannot be shipped to your state.
Is my Hims account private?
Yes, within standard HIPAA limits. Hims publishes a HIPAA-compliant Notice of Privacy Practices and treats intake answers as protected health information (PHI), encrypted in transit and at rest. Your data is shared with your prescribing clinician, the dispensing pharmacy, and limited internal Hims support staff. Marketing communications can be opted out in account settings. Shipping is discreet — packaging does not identify the medication or sender as Hims on the exterior.
What is the $149 Hims charge?
The $149 Hims charge that appears on customer statements is typically a monthly membership fee billed separately from medication. On some funnels (often weight-loss adjacent), Hims presents a membership that bundles support services. Cancelling your medication does NOT auto-cancel this membership — they are treated as independent subscriptions in Hims’ billing system. This is the dominant billing-confusion pattern across BBB and Trustpilot complaints. To cancel both, see our how to cancel Hims guide.
[provider=”hims”]
Sources
- FDA Warning Letter 716567 — Hims & Hers Health, Inc. dba Hims (September 9, 2025)
- Hims & Hers FY2025 Q4 and Full-Year Financial Results (Feb 23, 2026)
- Hims & Hers Health, Inc. 10-K filing (FY2025)
- Novo Nordisk press release — termination of Hims partnership (June 24, 2025)
- Trustpilot profile — hims.com (verified May 2026)
- BBB profile — Hims & Hers Inc. (verified May 2026)
- Out-of-Pocket — clinical model comparison across DTC telehealth
- Reuters — Novo Nordisk ends Hims partnership coverage
Related Reading
- Hims full provider review (canonical)
- Ro / Roman full provider review
- Hims FDA Warning Letter 716567 — Plain-English Explainer
- How to Cancel Hims in 2026 (Step-by-Step)
- Hims Pricing & Cost Breakdown 2026
- Is Roman Legit for ED? — same trust framework applied to Ro
- BlueChew FDA Warning Letter — comparison context
- BestMedsHub ED treatment hub
Medical disclaimer: Information here is educational only. Telehealth licensure, FDA enforcement status, and partnership terms are verified as of May 2026 from primary sources and are subject to change. This article is not legal, financial, or medical advice. Consult a licensed clinician before starting any prescription medication.